Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

This study examined dermoscopic features in African-American women with different types of alopecia and found that a perifollicular pink blush, potentially indicating inflammation, was common, particularly resolved with anti-inflammatory treatment, suggesting dermoscopy could aid in management.

This letter to the editor discusses immune checkpoint inhibitor-related alopecia and insights into its pathophysiology using non-invasive diagnostic techniques, but reports no new clinical results.

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.

Tocilizumab might be an effective treatment for COVID-19.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.

The authors describe drug repurposing as a promising strategy for finding new uses for existing drugs, noting it is efficient, cost-effective, and poses lower risks than traditional drug discovery processes, potentially aiding in the treatment of rare and difficult-to-treat diseases.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This review discusses the clinical characteristics of alopecia in cancer patients, highlighting its potential role as an associated finding or diagnostic clue, but reports no new clinical results.

This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

In this review, researchers explored the multifaceted role of NF-κB signaling in various biological processes and diseases, including its interactions with other pathways, and discussed possible therapeutic approaches targeting this pathway for treating conditions like cancer, autoimmune disorders, and COVID-19.

This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This review highlights the diverse cutaneous manifestations in immunocompromised patients, emphasizing the importance of early recognition for improved patient prognosis.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

In this case report, the authors documented a fatal instance of Stevens-Johnson syndrome in an elderly woman potentially triggered by doxycycline and flucloxacillin, emphasizing the importance of recognizing such rare but severe drug reactions in older patients.

In this study, lung cancer patients undergoing treatment with immune checkpoint inhibitors and chemotherapy reported high incidence and severity of symptoms such as fatigue, drowsiness, and loss of appetite, which were most prominent and distressing throughout the treatment cycles.

In this study, TENS of the T6 dermatome over a longer term was explored for its effects on weight, blood pressure, heart rate, and appetite-regulating hormones in obese subjects with moderate obstructive sleep apnea; however, results are not reported in the abstract.

This study introduces Kalya Research, an AI-driven tool designed to identify and categorize literature on complementary and alternative medicines, showing its effectiveness compared to Medline in finding relevant alopecia research within the context of breast cancer patients.

In this review, chemotherapy-induced alopecia in cancer patients is linked to drug pharmacology, genetics, and nutrition, affecting patients' mental health; scalp cooling is highlighted as an effective prevention method, but more research is needed for broader solutions.